Centers | ||
Chulalongkorn University Drug Discovery and Drug Development Research Center (Chula4DR) | Therapeutic Accelerator Program (TAP) | FDA Oncology Center of Excellence Project Catalyst |
Chulalongkorn
Drug Discovery and Drug Development Research Center (Chula4DR) was
established in 2017, with the aim to facilitate advancement of academic
drug discovery and drug development research by leveraging innovations
and sciences... Read more |
Test |
Providing a regulatory platform to connect scientific knowledge, creative insight, and medical professionals to foster early-stage product innovation |
Partnerships |
Events |
Jobs |
Senex BiotechnologyThe mission of Senex Biotechnology is to discover and develop therapeutic agents to effectively treat cancer, viral diseases and age-related diseases, such as Alzheimer's, renal disease, atherosclerosis, and arthritis, by targeting damage-inducible... View all Johns Hopkins BSi Licenses GCPII Assets from EisaiJohns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted... View all Evotec and Yale University form Open Innovation AllianceEvotec and Yale intend to leverage first rate science performed at Yale University together with Evotec's drug discovery infrastructure and expertise into highly innovative discovery approaches in diseases of high unmet medical need. Initially,... View all |
No EVENTS for listing |
No Job Posts |


